Why Science is Driving the Global Conversation on Tobacco Harm Reduction

Throughout history, some of the greatest advances in public health have come from challenging conventional thinking.

Vaccines transformed infectious disease prevention. Seatbelts reduced road fatalities. Antiretroviral therapy revolutionised HIV treatment. In each case, progress was achieved because policymakers and scientists remained open to innovation and evidence. Today, a similar conversation is unfolding in tobacco control.

As governments continue working to reduce smoking-related risks, growing attention is being given to Tobacco Harm Reduction (THR), a science-based approach that asks a simple but important question: for adult smokers who would otherwise continue smoking, can access to smoke-free alternatives help reduce the health risks associated with cigarette use?

For decades, scientific research has demonstrated that the greatest harms associated with smoking arise primarily from the burning of tobacco. When a cigarette burns, it generates thousands of chemicals, many of which are linked to cancer, cardiovascular disease and respiratory illnesses.

This understanding has prompted researchers, regulators and public health authorities to explore whether adult smokers who completely switch away from combustible cigarettes may reduce their exposure to many of these harmful substances through the use of scientifically substantiated smoke-free alternatives.

Importantly, this conversation is not about suggesting that nicotine products are risk-free. Nicotine is addictive, and the best choice for any smoker is to quit entirely. However, for millions of smokers who continue to smoke despite repeated quit attempts, a growing body of research is examining whether a complete switch away from combustible cigarettes may represent a better alternative than continued smoking.

That is why Tobacco Harm Reduction has become one of the most closely studied areas in contemporary tobacco science. The increasing interest in Tobacco Harm Reduction is not happening in isolation. Several countries have become important case studies for researchers and policymakers seeking to understand how different approaches may contribute to reducing cigarette smoking.

Sweden, for example, has achieved one of the lowest smoking prevalence rates in Europe. Japan has also attracted global attention following significant reductions in cigarette sales during the period in which heated tobacco products became available. Research has suggested that a decline in cigarette sales accelerated after these products entered the market, although the interaction of multiple factors continues to be studied.

The United Kingdom and New Zealand have likewise incorporated regulated smoke-free alternatives into broader approaches aimed at supporting adult smokers while maintaining strong youth-protection measures and regulatory oversight.

While no two countries have taken exactly the same path, a common theme has emerged: policymakers are increasingly willing to evaluate all evidence-based options that may help reduce smoking-related harm.

Nigeria has made important progress in tobacco control through legislation, smoke-free policies, public education initiatives and implementation of the WHO Framework Convention on Tobacco Control. These achievements should be protected and strengthened.

However, public health policy is most effective when it continues to evolve alongside emerging scientific evidence. The Tobacco Harm Reduction conversation should therefore not be viewed as a challenge to tobacco control. Rather, it should be viewed as part of a broader discussion about how best to reduce smoking-related risks among adults who continue to smoke.

The key question is straightforward: if evidence demonstrates that some nicotine products present significantly lower risks than combustible cigarettes, should adult smokers have access to accurate information and appropriately regulated alternatives? Increasingly, countries around the world are considering that question. Nigeria should not exclude itself from that important conversation.

One of the most significant gaps in the global Tobacco Harm Reduction debate is the limited amount of African research available. Most published studies originate from Europe, North America and parts of Asia. Yet African countries have unique public health, economic and demographic realities that deserve consideration in global discussions.

Nigeria, with its expanding healthcare infrastructure, respected academic institutions and growing research capacity, is well positioned to contribute meaningful local evidence. Universities, teaching hospitals and public health institutions can play a leading role in generating independent research on smoking behaviour, consumer patterns and health outcomes within African populations. Strong public policy depends on strong local evidence.

The future of tobacco control is unlikely to be defined by a single intervention.
Success will depend on the ability of science, regulation and public health policy to work together in pursuit of a common objective: reducing smoking-related risks and protecting public health. This is why the Tobacco Harm Reduction debate matters.

At its core, it is not a debate about products. It is a debate about outcomes. It is about whether science can help identify better options for adult smokers who would otherwise continue smoking, while maintaining robust safeguards to prevent youth uptake and protect non-users.

As new evidence continues to emerge, Nigeria has an opportunity to approach the issue with the same principle that has guided successful public health advances throughout history: remain open to evidence, follow the science, and focus relentlessly on improving health outcomes.